Your browser doesn't support javascript.
loading
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer, Ruth; Vidal, Laura; Griffin, Melanie; Lesley, Mark; de Bono, Johann; Coulthard, Sally; Sludden, Julieann; Siu, Lillian L; Chen, Eric X; Oza, Amit M; Reid, Gregory K; McLeod, A Robert; Besterman, Jeffrey M; Lee, Chooi; Judson, Ian; Calvert, Hilary; Boddy, Alan V.
Affiliation
  • Plummer R; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Ruth.plummer@ncl.ac.uk
Clin Cancer Res ; 15(9): 3177-83, 2009 May 01.
Article in En | MEDLINE | ID: mdl-19383817

Full text: 1 Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Thionucleotides / DNA (Cytosine-5-)-Methyltransferases / Enzyme Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2009 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Thionucleotides / DNA (Cytosine-5-)-Methyltransferases / Enzyme Inhibitors / Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2009 Type: Article Affiliation country: United kingdom